Supplemental Figure S4 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

Supplemental Figure S4 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

<p>Supplemental Figure S4 shows abundance of individual barcoded clones.</p>

Guardat en:

Dades bibliogràfiques
Autor principal:	Jennifer L. Cotton (17315204) (author)
Altres autors:	Javier Estrada Diez (17315207) (author), Vivek Sagar (17315210) (author), Julie Chen (17315213) (author), Michelle Piquet (15460169) (author), John Alford (17315216) (author), Youngchul Song (17315219) (author), Xiaoyan Li (17315222) (author), Markus Riester (17315225) (author), Matthew T. DiMare (17315228) (author), Katja Schumacher (17315231) (author), Gaylor Boulay (17315234) (author), Kathleen Sprouffske (15099146) (author), Lin Fan (17315237) (author), Tyler Burks (17315240) (author), Leandra Mansur (17315243) (author), Joel Wagner (17315246) (author), Hyo-eun C. Bhang (17315249) (author), Oleg Iartchouk (17315252) (author), John Reece-Hoyes (17315255) (author), Erick J. Morris (17315258) (author), Peter S. Hammerman (17315261) (author), David A. Ruddy (15460166) (author), Joshua M. Korn (17315264) (author), Jeffrey A. Engelman (17315267) (author), Matthew J. Niederst (17315270) (author)
Publicat:	2025
Matèries:	Cancer Tumor Biology Therapeutic Research and Development Methods and Technology Drug Resistance Lung Cancer Single Cell Technologies Tumor Heterogeneity
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars

Supplemental Figure S1 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
per: Jennifer L. Cotton (17315204)
Publicat: (2025)

Supplemental Figure S2 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
per: Jennifer L. Cotton (17315204)
Publicat: (2025)

Supplemental Figure S3 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
per: Jennifer L. Cotton (17315204)
Publicat: (2025)

Supplemental Figure S5 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
per: Jennifer L. Cotton (17315204)
Publicat: (2025)

Supplemental Figure S6 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
per: Jennifer L. Cotton (17315204)
Publicat: (2025)

Supplemental Figure S7 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
per: Jennifer L. Cotton (17315204)
Publicat: (2025)

Supplemental Figure S8 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
per: Jennifer L. Cotton (17315204)
Publicat: (2025)

Supplemental Tables 1 - 12 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
per: Jennifer L. Cotton (17315204)
Publicat: (2025)

Figure 1 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
per: Robert L. Hollis (15034814)
Publicat: (2025)

Figure 2 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
per: Robert L. Hollis (15034814)
Publicat: (2025)

Figure 3 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
per: Robert L. Hollis (15034814)
Publicat: (2025)

Figure 4 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
per: Robert L. Hollis (15034814)
Publicat: (2025)

Figure 5 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
per: Robert L. Hollis (15034814)
Publicat: (2025)

Table 1 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
per: Robert L. Hollis (15034814)
Publicat: (2025)

File_S1 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
per: Stéphane Fattori (15048281)
Publicat: (2025)

Table S1 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
per: Stéphane Fattori (15048281)
Publicat: (2025)

Table S2 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
per: Stéphane Fattori (15048281)
Publicat: (2025)

Table S3 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
per: Stéphane Fattori (15048281)
Publicat: (2025)

Table S4 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
per: Stéphane Fattori (15048281)
Publicat: (2025)

Table S5 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
per: Stéphane Fattori (15048281)
Publicat: (2025)

Table S6 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
per: Stéphane Fattori (15048281)
Publicat: (2025)

Table S7 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
per: Stéphane Fattori (15048281)
Publicat: (2025)

Table S8 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
per: Stéphane Fattori (15048281)
Publicat: (2025)

Supplemental Tables 1-8 from Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated <i>SPP1</i><sup>+</sup> Macrophages and Fibroblasts
per: Anuja Sathe (15028097)
Publicat: (2025)

Supplemental Table 1 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
per: Morten Lapin (15056728)
Publicat: (2025)

Supplemental Table 2 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
per: Morten Lapin (15056728)
Publicat: (2025)

Supplemental Table 3 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
per: Morten Lapin (15056728)
Publicat: (2025)

Supplementary Table S1 from Integrative Single-Cell and Bulk Transcriptomes Analyses Identify Intrinsic HNSCC Subtypes with Distinct Prognoses and Therapeutic Vulnerabilities
per: Yibin Dai (16374331)
Publicat: (2025)

Supplementary Table S2 from Integrative Single-Cell and Bulk Transcriptomes Analyses Identify Intrinsic HNSCC Subtypes with Distinct Prognoses and Therapeutic Vulnerabilities
per: Yibin Dai (16374331)
Publicat: (2025)

Table S1 from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
per: Guillaume Davidson (14964069)
Publicat: (2025)

Table S2 from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
per: Guillaume Davidson (14964069)
Publicat: (2025)

Table S3 from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
per: Guillaume Davidson (14964069)
Publicat: (2025)

Table S4 from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
per: Guillaume Davidson (14964069)
Publicat: (2025)

Table S9 from Cross-talk between Myeloid and B Cells Shapes the Distinct Microenvironments of Primary and Secondary Liver Cancer
per: Zhihang Chen (17315678)
Publicat: (2025)

Supplementary Table1 from USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer
per: Yidan Ren (14845140)
Publicat: (2025)

Supplementary Table2 from USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer
per: Yidan Ren (14845140)
Publicat: (2025)

Supplementary Table3 from USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer
per: Yidan Ren (14845140)
Publicat: (2025)

Suppl video 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
per: Andrew O. Yam (15293045)
Publicat: (2025)

Suppl video 2 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
per: Andrew O. Yam (15293045)
Publicat: (2025)

Suppl video 3 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
per: Andrew O. Yam (15293045)
Publicat: (2025)

Cannot write session to /tmp/vufind_sessions/sess_lt98lun07gvcg724rondkc5esr